Retension Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 11.83 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 98.56M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascular disease. The company was incorporated in 2023 and is headquartered in...